Roivant Sciences (ROIV) affiliate boosts Immunovant stake with 16,666,666-share buy

Rhea-AI Filing Summary

Immunovant, Inc. reported an insider transaction by a reporting person who is both a director and a 10% owner. On December 12, 2025, this filer purchased 16,666,666 shares of Immunovant common stock at $21 per share. Following the transaction, the filer directly beneficially owned 113,317,007 Immunovant shares. The filer is considered a director by deputization because senior executives of Roivant Sciences, Inc., a subsidiary of the reporting person, currently serve on Immunovant’s board on its behalf.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roivant Sciences Ltd.

(Last) (First) (Middle)

7TH FLOOR

50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 par value per share	12/12/2025		P		16,666,666	A	$21	113,317,007	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The Reporting Person is deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Frank M. Torti, M.D. (who serves as President & Vant Chair of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person), Eric Venker, M.D., Pharm.D. (who serves as President of RSI) and Andrew Fromkin (who serves as the Vant Portfolio Operating Partner for RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person.

	/s/ Keyur Parekh, as Authorized Signatory	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction related to Immunovant (IMVT) was reported by the ROIV-affiliated holder?

A reporting person who is a director and 10% owner reported buying 16,666,666 shares of Immunovant common stock at $21 per share on December 12, 2025.

How many Immunovant shares does the reporting person beneficially own after the transaction?

After the reported purchase, the filer directly beneficially owned 113,317,007 shares of Immunovant common stock.

What is the relationship of the reporting person to Immunovant, Inc.?

The reporting person is identified as both a director and a 10% owner of Immunovant, Inc.

What does director by deputization mean in this Immunovant/ROIV filing?

The filer is deemed a director by deputization because executives of Roivant Sciences, Inc., a subsidiary of the reporting person, serve on Immunovant’s board on its behalf.

Which Roivant Sciences executives are on Immunovant’s board on behalf of the reporting person?

The filing notes Frank M. Torti, M.D., Eric Venker, M.D., Pharm.D., and Andrew Fromkin as Immunovant directors serving on behalf of the reporting person.

Was the reported transaction in this Form 4 for derivative or non-derivative securities?

The disclosed transaction involved non-derivative securities, specifically Immunovant common stock, as shown in Table I.